Omada Health (NASDAQ:OMDA) CAO Craig Gracey Sells 1,042 Shares of Stock

Key Points

• Omada Health CAO Craig Gracey sold 1,042 shares at an average price of $25, generating $26,050 and reducing his direct ownership by 6.32% to 15,441 shares. The sale follows several additional insider sales in recent months.
• Omada reported stronger-than-expected second-quarter results, with earnings of $0.08 per share versus an expected loss of $0.02 and revenue of $87.83 million versus an $80.93 million consensus estimate.
• The stock traded around $23.84, while analysts maintained a broadly favorable “Moderate Buy” consensus and an average price target near $25.75. However, its roughly 477 P/E ratio signals significant valuation risk if growth or profitability disappoints.

Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CAO Craig Gracey sold 1,042 shares of Omada Health stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $26,050.00. Following the sale, the chief accounting officer directly owned 15,441 shares in the company, valued at approximately $386,025. This trade represents a 6.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Craig Gracey also recently made the following trade(s):

• On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The shares were sold at an average price of $23.00, for a total value of $14,651.00.
• On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The stock was sold at an average price of $22.00, for a total value of $8,910.00.
• On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $21.00, for a total value of $43,743.00.
• On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The shares were sold at an average price of $20.00, for a total value of $41,680.00.
• On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $19.01, for a total value of $39,597.83.
• On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $18.00, for a total transaction of $37,494.00.
• On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48.

Omada Health Stock Down 0.7%

Omada Health stock traded down $0.17 on Wednesday, hitting $23.84. The company's stock had a trading volume of 1,552,408 shares, compared to its average volume of 1,274,695. Omada Health, Inc. has a one year low of $10.28 and a one year high of $26.92. The firm has a market cap of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. The company has a fifty day moving average price of $20.61 and a 200-day moving average price of $16.32.

Omada Health (NASDAQ:OMDA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.10. The company had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. Analysts anticipate that Omada Health, Inc. will post -0.01 EPS for the current year.

Institutional Trading of Omada Health

Several large investors have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new position in shares of Omada Health in the second quarter valued at about $44,402,000. BlackRock Inc. acquired a new stake in Omada Health in the 2nd quarter valued at about $48,775,000. Millennium Management LLC increased its position in Omada Health by 1,195.0% in the 4th quarter. Millennium Management LLC now owns 2,272,168 shares of the company's stock valued at $35,855,000 after acquiring an additional 2,096,705 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Omada Health in the fourth quarter worth about $16,948,000. Finally, SG Americas Securities LLC acquired a new position in shares of Omada Health during the first quarter worth approximately $10,401,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on OMDA shares. Barclays raised their target price on Omada Health from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. The Goldman Sachs Group reiterated a "buy" rating on shares of Omada Health in a research report on Friday, May 8th. Robert W. Baird increased their price objective on Omada Health from $15.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday. Citigroup reissued an "outperform" rating on shares of Omada Health in a report on Monday, July 20th. Finally, BMO Capital Markets restated an "outperform" rating and issued a $24.00 target price on shares of Omada Health in a research note on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Omada Health presently has a consensus rating of "Moderate Buy" and an average price target of $25.75.

Omada Health News Summary

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
• Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
• Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source